Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/PS1 mice and human brain organoid models

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · see citing works

fastp: an ultra-fast all-in-one FASTQ preprocessor

(2018) · doi:10.1093/bioinformatics/bty560 · Cited by 29,721 · see citing works

HISAT: a fast spliced aligner with low memory requirements

Kim, D., Langmead, B., & Salzberg, S. L. (2015) · Nature Methods · doi:10.1038/nmeth.3317 · Cited by 24,112 · see citing works

HTSeq—a Python framework to work with high-throughput sequencing data

Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464 · see citing works

Neurotoxic reactive astrocytes are induced by activated microglia

Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971 · see citing works

Alzheimer's disease

Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465 · see citing works

Cerebral organoids model human brain development and microcephaly

Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372 · see citing works

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · see citing works

Comprehensive Review on Alzheimer’s Disease: Causes and Treatment

Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789 · see citing works

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · see citing works

Glucagon-like peptide 1 (GLP-1)

Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · see citing works

Improving RNA-Seq expression estimates by correcting for fragment bias

Roberts, A., Trapnell, C., Donaghey, J., Rinn, J. L., & Pachter, L. (2011) · Genome Biology · doi:10.1186/gb-2011-12-3-r22 · Cited by 1,725 · see citing works

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art

Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · see citing works

Cell diversity and network dynamics in photosensitive human brain organoids

Quadrato, G., Nguyen, T., Macosko, E. Z., Sherwood, J. L., Min Yang, S., Berger, D. R., Maria, N., Scholvin, J., Goldman, M., Kinney, J. P., et al. (2017) · Nature · doi:10.1038/nature22047 · Cited by 1,321 · see citing works

Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches

Kellar, D., & Craft, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30231-3 · Cited by 832 · see citing works

Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease

Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820 · see citing works

Semaglutide lowers body weight in rodents via distributed neural pathways.

Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · see citing works

Alzheimer’s Disease: Epidemiology and Clinical Progression

Tahami Monfared, A. A., Byrnes, M. J., White, L. A., & Zhang, Q. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00338-8 · Cited by 629 · see citing works

The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin

Davies, H. G., Richter, R. J., Keifer, M., Broomfield, C. A., Sowalla, J., & Furlong, C. E. (1996) · Nature Genetics · doi:10.1038/ng1196-334 · Cited by 594 · see citing works

Human Astrocyte Maturation Captured in 3D Cerebral Cortical Spheroids Derived from Pluripotent Stem Cells

Sloan, S. A., Darmanis, S., Huber, N., Khan, T. A., Birey, F., Caneda, C., Reimer, R., Quake, S. R., Barres, B. A., & Paşca, S. P. (2017) · Neuron · doi:10.1016/j.neuron.2017.07.035 · Cited by 593 · see citing works

Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials

Ossenkoppele, R., van der Kant, R., & Hansson, O. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00168-5 · Cited by 557 · see citing works

The complexity of Alzheimer’s disease: an evolving puzzle

Ferrari, C., & Sorbi, S. (2021) · Physiological Reviews · doi:10.1152/physrev.00015.2020 · Cited by 324 · see citing works

Early stages of tau pathology and its associations with functional connectivity, atrophy and memory

Berron, D., Vogel, J. W., Insel, P. S., Pereira, J. B., Xie, L., Wisse, L. E. M., Yushkevich, P. A., Palmqvist, S., Mattsson-Carlgren, N., Stomrud, E., et al. (2021) · Brain · doi:10.1093/brain/awab114 · Cited by 240 · see citing works

Accelerated Plaque Accumulation, Associative Learning Deficits, and Up-regulation of α7 Nicotinic Receptor Protein in Transgenic Mice Co-expressing Mutant Human Presenilin 1 and Amyloid Precursor Proteins

Dineley, K. T., Xia, X., Bui, D., Sweatt, J. D., & Zheng, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200164200 · Cited by 212 · see citing works

Modeling Sporadic Alzheimer's Disease in Human Brain Organoids under Serum Exposure

Chen, X., Sun, G., Tian, E., Zhang, M., Davtyan, H., Beach, T. G., Reiman, E. M., Blurton‐Jones, M., Holtzman, D. M., & Shi, Y. (2021) · Advanced Science · doi:10.1002/advs.202101462 · Cited by 200 · see citing works

Updates on mouse models of Alzheimer’s disease

Zhong, M. Z., Peng, T., Duarte, M. L., Wang, M., & Cai, D. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00712-0 · Cited by 189 · see citing works

Co-expression patterns of microglia markers Iba1, TMEM119 and P2RY12 in Alzheimer’s disease

Kenkhuis, B., Somarakis, A., Kleindouwel, L. R. T., van Roon-Mom, W. M. C., Höllt, T., & van der Weerd, L. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105684 · Cited by 188 · see citing works

Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks

Peng, Y., Jin, H., Xue, Y.-H., Chen, Q., Yao, S., Du, M., & Liu, S. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1206572 · Cited by 176 · see citing works

A Shortened Barnes Maze Protocol Reveals Memory Deficits at 4-Months of Age in the Triple-Transgenic Mouse Model of Alzheimer's Disease

Attar, A., Liu, T., Chan, W.-T. C., Hayes, J., Nejad, M., Lei, K., & Bitan, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080355 · Cited by 161 · see citing works

Oxytocin stimulates hippocampal neurogenesis via oxytocin receptor expressed in CA3 pyramidal neurons

Lin, Y.-T., Chen, C., Huang, C., Nishimori, K., & Hsu, K. (2017) · Nature Communications · doi:10.1038/s41467-017-00675-5 · Cited by 149 · see citing works

Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases

Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148 · see citing works

Alzheimer’s disease-associated (hydroxy)methylomic changes in the brain and blood

Lardenoije, R., Roubroeks, J. A. Y., Pishva, E., Leber, M., Wagner, H., Iatrou, A., Smith, A. R., Smith, R. G., Eijssen, L., Kleineidam, L., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0755-5 · Cited by 136 · see citing works

Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice

McClean, P. L., Jalewa, J., & Hölscher, C. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.024 · Cited by 125 · see citing works

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease

Du, H., Meng, X., Yao, Y., & Xu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1033479 · Cited by 125 · see citing works

Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway

Wang, Z.-J., Li, X.-R., Chai, S.-F., Li, W.-R., Li, S., Hou, M., Li, J.-L., Ye, Y.-C., Cai, H.-Y., Hölscher, C., et al. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109716 · Cited by 125 · see citing works

Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer’s disease

Dong, Y., Yu, H., Li, X., Bian, K., Zheng, Y., Dai, M., Feng, X., Sun, Y., He, Y. T., Yu, B., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02567-y · Cited by 123 · see citing works

Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews

Pérez, M., Burgos‐Alonso, N., Torrecilla, M., Marco‐Contelles, J., & Bruzos-Cidón, C. (2021) · Biomedicines · doi:10.3390/biomedicines9111689 · Cited by 110 · see citing works

Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review

Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03302-1 · Cited by 110 · see citing works

Quantitative histological analysis of amyloid deposition in Alzheimer’s double transgenic mouse brain

Wengenack, T. M., Whelan, S. L., Curran, G. L., Duff, K., & Poduslo, J. F. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00388-2 · Cited by 97 · see citing works

Semaglutide: review and place in therapy for adults with type 2 diabetes

Goldenberg, R. M., & Steen, O. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.05.008 · Cited by 91 · see citing works

Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis

Chang, Y.-F., Zhang, D., Hu, W., Liu, D.-X., & Li, L. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.09.054 · Cited by 80 · see citing works

Distribution of glucagon-like peptide-1 immunoreactivity in the hypothalamic paraventricular and supraoptic nuclei

Tauchi, M., Zhang, R., D’Alessio, D. A., Stern, J. E., & Herman, J. P. (2008) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2008.07.009 · Cited by 79 · see citing works

Liraglutide Suppresses Tau Hyperphosphorylation, Amyloid Beta Accumulation through Regulating Neuronal Insulin Signaling and BACE-1 Activity

Jantrapirom, S., Nimlamool, W., Chattipakorn, N., Chattipakorn, S. C., Temviriyanukul, P., Inthachat, W., Govitrapong, P., & Potikanond, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051725 · Cited by 63 · see citing works

The Interplay Between Beta-Amyloid 1–42 (Aβ1–42)-Induced Hippocampal Inflammatory Response, p-tau, Vascular Pathology, and Their Synergistic Contributions to Neuronal Death and Behavioral Deficits

Guzmán, B. C., Chaffey, T. E., Palpagama, T. H., Waters, S., Boix, J., Tate, W. P., Peppercorn, K., Dragunow, M., Waldvogel, H. J., Faull, R. L. M., et al. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.552073 · Cited by 59 · see citing works

Amyloid and tau pathology of familial Alzheimer’s disease APP/PS1 mouse model in a senescence phenotype background (SAMP8)

Porquet, D., Andrés-Benito, P., Griñán-Ferré, C., Camins, A., Ferrer, I., Canudas, A. M., Del Valle, J., & Pallàs, M. (2015) · AGE · doi:10.1007/s11357-015-9747-3 · Cited by 53 · see citing works

Oxytocin reverses Aβ-induced impairment of hippocampal synaptic plasticity in mice

Takahashi, J., Yamada, D., Ueta, Y., Iwai, T., Koga, E., Tanabe, M., Oka, J., & Saitoh, A. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.04.046 · Cited by 45 · see citing works

Coexpression of Glucagon‐Like Peptide‐1 (GLP‐1) Receptor, Vasopressin, and Oxytocin mRNAs in Neurons of the Rat Hypothalamic Supraoptic and Paraventricular Nuclei

Zueco, J. A., Esquifino, A. I., Chowen, J. A., Álvarez, E., Castrillón, P. O., & Blázquez, E. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720010.x · Cited by 44 · see citing works

Beneficial synergistic effects of microdose lithium with pyrroloquinoline quinone in an Alzheimer's disease mouse model

Zhao, L., Gong, N., Liu, M., Pan, X., Sang, S., Sun, X., Yu, Z., Fang, Q., Zhao, N., Fei, G., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.003 · Cited by 44 · see citing works

Regulating microglial miR-155 transcriptional phenotype alleviates Alzheimer’s-induced retinal vasculopathy by limiting Clec7a/Galectin-3+ neurodegenerative microglia

Shi, H., Yin, Z., Koronyo, Y., Fuchs, D.-T. S., Sheyn, J., Davis, M. R., Wilson, J. W., Margeta, M. A., Pitts, K. M., Herron, S., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01439-z · Cited by 44 · see citing works

Oxytocin Rapidly Changes Astrocytic GFAP Plasticity by Differentially Modulating the Expressions of pERK 1/2 and Protein Kinase A

Wang, P., Qin, D., & Wang, Y. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00262 · Cited by 44 · see citing works

Deficits in N-Methyl-D-Aspartate Receptor Function and Synaptic Plasticity in Hippocampal CA1 in APP/PS1 Mouse Model of Alzheimer’s Disease

Xu, L., Zhou, Y., Hu, L., Jiang, H., Dong, Y.-B., Shen, H., Lou, Z., Yang, S., Ji, Y., Ruan, L., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.772980 · Cited by 43 · see citing works

Accelerated aging exacerbates a pre‐existing pathology in a tau transgenic mouse model

Bodea, L., Evans, H. T., der Jeugd, A. V., Ittner, L. M., Delerue, F., Kril, J. J., Halliday, G. M., Hodges, J. R., Kiernan, M. C., & Götz, J. (2017) · Aging Cell · doi:10.1111/acel.12565 · Cited by 39 · see citing works

Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model

Morales‐Corraliza, J., Schmidt, S. D., Mazzella, M. J., Berger, J. D., Wilson, D. A., Wesson, D. W., Jucker, M., Levy, E., Nixon, R. A., & Mathews, P. M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.007 · Cited by 34 · see citing works

Intracerebroventricular administration of oxytocin and intranasal administration of the oxytocin derivative improve β‐amyloid peptide (25–35)‐induced memory impairment in mice

Takahashi, J., Ueta, Y., Yamada, D., Sasaki‐Hamada, S., Iwai, T., Akita, T., Yamashita, C., Saitoh, A., & Oka, J. (2022) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12292 · Cited by 33 · see citing works

The Role of Oxytocin in Alzheimer’s Disease and Its Relationship with Social Interaction

Takahashi, J., Yamada, D., Nagano, W., & Saitoh, A. (2023) · Cells · doi:10.3390/cells12202426 · Cited by 25 · see citing works

Participatory Research Approaches in Alzheimer’s Disease and Related Dementias Literature: A Scoping Review

Reyes, L., Scher, C. J., & Greenfield, E. A. (2023) · Innovation in Aging · doi:10.1093/geroni/igad091 · Cited by 23 · see citing works

In Silico Drug Design and Analysis of Dual Amyloid-Beta and Tau Protein-Aggregation Inhibitors for Alzheimer’s Disease Treatment

Job, N., Thimmakondu, V. S., & Thirumoorthy, K. (2023) · Molecules · doi:10.3390/molecules28031388 · Cited by 23 · see citing works

Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease

Mashal, Y., Abdelhady, H. G., & Iyer, A. K. (2022) · Biomolecules · doi:10.3390/biom12071001 · Cited by 20 · see citing works

Alzheimer’s Disease Markers in Aged ApoE-PON1 Deficient Mice

Narasimhulu, C. A., Mitra, C., Bhardwaj, D., Burge, K. Y., & Parthasarathy, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180883 · Cited by 19 · see citing works

The epidemiology of mild cognitive impairment, Alzheimer's disease and related dementia in U.S. veterans

Dinesh, D., Shao, Q., Palnati, M., McDannold, S. E., Zhang, Q., Monfared, A. A. T., Jasuja, G. K., Davila, H. W., Xia, W., Moo, L. R., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13071 · Cited by 16 · see citing works

Long-Term Effect of Acetylcholinesterase Inhibitors on the Dorsal Attention Network of Alzheimer’s Disease Patients: A Pilot Study Using Resting-State Functional Magnetic Resonance Imaging

Yamashita, K., Uehara, T., Taniwaki, Y., Tobimatsu, S., & Kira, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.810206 · Cited by 15 · see citing works

Antagonistic interaction between central glucagon-like Peptide-1 and oxytocin on diet-induced obesity mice

Lee, J., Moon, H., Lee, H., Oh, Y., Kim, C., Lee, Y. H., Kim, M. S., NamKoong, C., Lee, H. W., Kim, J. H., et al. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05190 · Cited by 8 · see citing works

Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity

Lin, H.-T., Tsai, Y.-F., Liao, P.-L., & Wei, J. C.-C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.21016 · Cited by 43 · see citing works

Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer’s Disease

Urkon, M., Ferencz, E., Szász, J. A., Szabó, M. I. M., Orbán-Kis, K., Szatmári, S., & Nagy, E. E. (2025) · Pharmaceuticals · doi:10.3390/ph18050614 · Cited by 40 · see citing works

GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy

Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1675552 · Cited by 36 · see citing works

Associations of semaglutide with Alzheimer's disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study

Wang, W., Davis, P. B., Qi, X., Gurney, M. E., Perry, G. L., Volkow, N. D., Kaelber, D. C., & Xu, R. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251351329 · Cited by 33 · see citing works

CRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability

He, Y., Tu, X., Xue, Y., Chen, Y., Ye, B., Li, X., Li, D., Zhong, Z., & Zhong, Q. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101357 · Cited by 30 · see citing works

The promise of GLP-1 receptor agonists for neurodegenerative diseases

Athauda, D. S., Greig, N. H., Meissner, W. G., Foltynie, T., & Gandhi, S. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194745 · Cited by 30 · see citing works

Incretin-based therapeutics for the treatment of neurodegenerative diseases

Vear, A., Heneka, M. T., & Clemmensen, C. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01263-4 · Cited by 21 · see citing works

Single-cell sequencing and organoids: applications in organ development and disease

Li, T., Yin, J., Hao, Y., Gao, W., Li, Q., Feng, Q., Tao, B., Hao, M., Liu, Y., Lin, C., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00364-6 · Cited by 19 · see citing works

Beyond diabetes and obesity: GLP ‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation

Spezani, R., & Mandarim‐de‐Lacerda, C. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70400 · Cited by 19 · see citing works

Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies

Corraliza-Gómez, M., Vargas-Soria, M., & Garcı́a-Alloza, M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00894-1 · Cited by 13 · see citing works

Advances and applications of brain organoids in central nervous system disorders: Bridging the gap from laboratory to clinic

Fang, C., Wang, Q., Xiao, Q., Cai, X.-X., Du, R., Xue, L., Tian, X., & Xiong, L. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01490 · Cited by 7 · see citing works

Targeting brain connectivity in Alzheimer’s disease with repurposed drugs

Pini, L., Imbimbo, B. P., Griffa, A., Allali, G., & Pomara, N. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.103001 · Cited by 7 · see citing works

Glucagon-Like Peptide-1 Receptor Agonists Are Promising for the Treatment of Brain Diseases: an Outlook from the Perspective of Integrative Physiology

Gulyaeva, N. V. (2025) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093025050023 · Cited by 7 · see citing works

Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide

Evola, V., & Parmar, M. S. (2026) · Inflammation Research · doi:10.1007/s00011-025-02166-6 · Cited by 7 · see citing works

The complexity of dementia development and its comorbidities: The collaborative cross‐mouse population for multivarious tasks approach

Zohud, O., Lone, I. M., Midlej, K., & Iraqi, F. A. (2026) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70131 · Cited by 4 · see citing works

Interaction Between Glucagon-like Peptide 1 and Its Analogs with Amyloid-β Peptide Affects Its Fibrillation and Cytotoxicity

Андреевна, Л. Е., Shevelyova, M. P., Андреевна, В. А., Deryusheva, E. I., Chaplygina, A. V., Rastrygina, V. A., Валериевич, М. А., Alikova, V. D., Nazipova, A. A., Permyakova, M. E., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094095 · Cited by 3 · see citing works

Microbiota gut-brain axis dysfunction in Alzheimer’s Disease: From pathogenesis to potential treatments – A review

Salman, B., Haidar, R., Faour, V., Ali, W. A., Aridi, L., Harb, F., Azar, S. T., Khattar, Z. A., & Ghadieh, H. E. (2025) · Health Sciences Review · doi:10.1016/j.hsr.2025.100251 · Cited by 2 · see citing works

Diet–microbiota–host interactions in regulation of cardiometabolic homeostasis: emerging mechanisms and therapeutic potential

Plata, A. A., Otmanowski, E., & Zubcevic, J. A. (2025) · Microbiota and Host · doi:10.1530/mah-25-0008 · Cited by 1 · see citing works

Organoids: Key advances, optimization, and technological iterations in their application to neurodegenerative diseases

Zhao, J., Wang, J., & Guo, X. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00924 · Cited by 1 · see citing works

Engineered exosomal delivery of semaglutide activates SIRT1–FOXO3a–miR-124 signaling and protects against cortical neuroinflammation

Elmorsy, E. A., Saber, S., Kira, A. Y., Hatem, M. M., Alorini, M., Morsy, S. A. A., Alsaykhan, H., Alsalloom, A. A., Mohamed, N. B., Alsoqih, N. S., et al. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108078 · Cited by 1 · see citing works

Developmental stage–dependent neurotoxicity of sevoflurane: evidence from brain organoids

Chen, N., Zhang, Y., Chen, Y., & Chen, G. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1774547 · Cited by 1 · see citing works

Sex differences in neuromodulatory subcortical systems and their implications for Alzheimer's disease

Rae, R. J., Alberhasky, J. M. H., Baillet, M., Bangasser, D. A., Belloy, M. E., Berry, A. S., Berteotti, C., Bow, H., Buckley, R. F., Caldwell, J. K., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71291 · Cited by 1 · see citing works

Semaglutide Selectively Improves Metabolic and Cognitive Function in 5xFAD Mice

Shahabian, L., Kynigopoulos, D., Papacharalambous, R., Ioannou, E., Dionysiou, S., Christou, S., Picolos, M. K., Pipis, M., & Panayiotou, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125311 · Cited by 1 · see citing works

Semaglutide as a potential neuroprotective agent for neurological and neurodegenerative disorders: Mechanisms, preclinical evidence, and translational challenges and opportunities

Mukim, R. D., Xu, Y., Evola, V., & Parmar, M. S. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12549-5 · Cited by 1 · see citing works

Glucose-Lowering Therapies and Cognitive Decline: From Molecular Mechanisms to Clinical Evidence and Future Perspectives

Grasso, M., Maggio, V., Caraci, F., & Rizzo, M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03760-8 · Cited by 1 · see citing works

THE ROLE OF INCRETIN-BASED THERAPIES IN ALZHEIMER’S DISEASE: FOCUS ON SEMAGLUTIDE - LITERATURE REVIEW

Derlatka, H., Bobrowski, B., Drugacz, J., Helbig, O., Kontek, K., Kukhtiak, A., Marcinkowska, J., Radelczuk, M., & Skowron, Ł. (2025) · Archiv Euromedica · doi:10.35630/2025/15/iss.5.501

The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer’s and Parkinson’s Disease: A Literature Review of Clinical Trials

Pilśniak, J., Węgrzynek‐Gallina, J., Bednarczyk, B., Buczek, A., Pilśniak, A., Chmiela, T., Jarosińska, A., Siuda, J. S., & Holecki, M. T. (2025) · Life · doi:10.3390/life15121893

Caveolin-1–Mediated Blood-brain Barrier Transcytosis Promotes Porphyromonas gingivalis Invasion and Alzheimer’s Disease-Like ChangesPreprint

Chenghan, M., Zhong, Q., Xiaojie, L., Yao, H., Zhang, T., Zhao, B., Jiangshang, L., & Zhihui, Z. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.17.706258

Intervention of ginseng-derived macromolecular drugs in Alzheimer’s disease: exploring mechanisms and assessing potential

Liu, W., Bai, Y., Qu, W., Zhang, X., Zhou, S., Luo, H., Zhu, M., Li, D., & Fang, X. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1752446

Semaglutide treatment reverses HFD induced hippocampal microglia activation and improves cognitive dysfunction

Gong, H., Liu, J., Wang, Y., Lin, X., Wu, G., Ou, Y., Zhou, M., le Yang, Peng, J., Ye, X., et al. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103495

Beyond diabetes management: A narrative review on the neurological and psychiatric impact of semaglutide

Weiss, A., & Ding, Y. (2026) · Brain Circulation · doi:10.4103/bc.bc_210_25

Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer’s disease: emerging therapeutic candidates

Manzine, P. R., Carrasco, M., Fernandes, T. A. A., Alves, S. S., Guzman, L., Driouech, L., Millet, M., Cairasco, N. G., Olloquequi, J., Juan, M. E., et al. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2710112

Semaglutide/Acarbose combination protects against diabetic nephropathy in rats; a novel insight into modulation of Nrf-2/HO-1& TGF-β/Smad pathways

Elborei, M., Ashour, A. A., El-Latif, H. A. E.-T. A., & Akool, E. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117277

Repurposing GLP-1 receptor agonists for Alzheimer's disease: Promise, pitfalls, and patient selection

Adhikari, S., Carlyle, B. C., & de Wet, H. (2026) · The Journal of Precision Medicine Health and Disease · doi:10.1016/j.premed.2026.100057

HIF-1 plays a dual regulatory role in hippocampal neuronal PANoptosis in Alzheimer's disease via the HK2/VDAC1/NLRP3 axis and RIPK3 signaling

Yang, L., Wang, S., Luo, L., Jiang, X., Ren, T., Liu, W., Hai, J., Zhou, X., & Li, Y. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108440

GLP-1 as a Regulator of Oxidative Signalling in Metabolic Health and Disease

Kurhaluk, N., Kołodziejska, R., & Ткаченко, Г. М. (2026) · Antioxidants · doi:10.3390/antiox15101283

Modulating Microglial Activation Through GLP‐1 Pathways: A New Frontier in Neuroinflammation Research

Lakshmi, S. M., Singh, V., Vanangamudi, M., Taj, T., Shahin, H., Nath, R., Dutta, G., Avvari, S. K., Sridhar, S. B., Panigrahy, U. P., et al. (2026) · European Journal of Neuroscience · doi:10.1111/ejn.70718

The "Invisible Killer” of Neurodegeneration: Mitochondrial Dysfunction in Neurodegenerative Disorders, Mechanisms, Emerging Pathways and Therapeutic Strategies

Cao, S., Liu, T., 程相树, Tian, X., & Wei, J. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s653025

Emerging and Repurposed Immune System Modulators for Alzheimer’s Disease

Decourt, B., Azarfar, K., Reyna, E. M., Kennedy, J. M., & Sabbagh, M. N. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s559284

Alzheimer's Disease: Mechanisms and Therapeutic Advances

Fu, G., Pan, M., Sun, Q., Yue, G.-X., & Lei, T. (2026) · MedComm · doi:10.1002/mco2.71093

Exploring the Impact of Semaglutide on Cognitive Function and Anxiety-Related Behaviors in a Murine Model of Alzheimer’s Disease

Boboc, I. K. Ş., Dumitrelea, P.-D., Meca, A.-D., Mititelu-Tarțău, L., & Bogdán, M. (2024) · Biomedicines · doi:10.3390/biomedicines12122689 · Cited by 9 · see citing works

Semaglutide improves cognitive function and neuroinflammation in APP/PS1 transgenic mice by activating AMPK and inhibiting TLR4/NF-κB pathway

Zhai, Y., Lu, K., Yuan, Y., Zhang, Z., Xue, L., Zhao, F., Xu, X., & Wang, H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251329439 · Cited by 24 · see citing works

Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway

Wang, Z.-J., Li, X.-R., Chai, S.-F., Li, W.-R., Li, S., Hou, M., Li, J.-L., Ye, Y.-C., Cai, H.-Y., Hölscher, C., et al. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109716 · Cited by 125 · see citing works

Semaglutide Improves Cognitive Function and Neuroinflammation in APP/PS1 Transgenic Mice by Inhibiting TLR4/NF-κB PathwayPreprint

Zhai, Y., Lu, K., Yuan, Y., Xue, L., Zhao, F., Xu, X., & Wang, H. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4680913

Effects of Semaglutide on Alzheimer’s Disease-related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer’s Disease After 12 Weeks of Treatment (S1.008)

Frederiksen, K., Mystkowski, P., Bentsen, M. A., Belmont-Rausch, D. M., Carstensen, L., Cutler, B., Farooq, R., Hildebrandt, L., Jiménez‐Mausbach, M., Johannsen, P., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000216961 · Cited by 2 · see citing works